Condrosulf® is a pharmaceutical formulation containing chondroitin sulfate (CS) as an active component possessing
high quality and purity and standardized properties. CS is currently applied as a SYSADOA (Symptomatic Slow
Acting Drug for Osteoarthritis) agent in Europe in the treatment of osteoarthritis (OA). Furthermore, Condrosulf® and
pharmaceutical grade CS have also been proven to possess structure-modifying effects belonging to the S/DMOAD
(structure/disease modifying anti-osteoarthritis drug) class. This review summarizes current knowledge on
CS/Condrosulf® structure and its properties, its pharmacological activity as proved by many clinical trials and metaanalysis
studies and focuses attention on its mechanisms of action in the pathophysiology of osteoarthritic joint tissues.
Finally, future perspectives are discussed in connection with the possibility to apply new outcome measures, such as MRI
and biomarkers, which can yield important advances in the use of Condrosulf® as well as the development of new drugs
with different structures useful in particular for the treatment of inflammatory symptoms and able to retard the progression
Keywords: Condrosulf®, chondroitin sulfate, glycosaminoglycans, osteoarthritis.
Rights & PermissionsPrintExport